Resumen de Equipotent doses of pegylated epoetin ß (CERA) for the treatment of outcome patients with anemia secondary to chronic kidney disease in clinical practice
Vicente Escudero Vilaplana, Sergio Plata Paniagua, Arantza Ais Larisgoitia, Carmen Guadalupe Rodríguez González, José M. Bellón Cano
Objective: To analyze the equipotent dose relationship between CERA with the rest of erythropoiesis-stimulating agents (ESA) in the treatment of the anemia secondary to chronic kidney disease (CKD) in clinical practice. Method: Descriptive cross-sectional study performed in the included adult outpatients on treatment with ESA for anemia secondary to CKD. Registered variables were: demographic, date of dispensing, type and dose of ESA, prescriber service, hemoglobin, serum creatinine, uremia, C-reactive protein (CRP), albumin and fibrinogen. We analyzed the differences in mean doses obtained regarding those recommended. Results: 136 patients were included. ESA was prescribed as epoetin a in 14% of patients (monthly mean dose, 15,842 IU [6,891]), epoetin ß in 17.6% (monthly mean dose, 16,454 IU [12,170]), darbepoetin a in 50% (monthly mean dose 109 mcg [91]), CERA in 18.4% (monthly mean dose, 75 mcg [47]). Conclusion: The doses of CERA used in clinical practice were lower than those recommended on label
